Synageva Biopharma Corp (GEVA) financial statements (2021 and earlier)

Company profile

Business Address 33 HAYDEN AVE.
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments447409219
Cash and cash equivalents836224
Short-term investments364347195
Receivables213
Prepaid expense11
Prepaid expense and other current assets4
Other current assets41
Other undisclosed current assets45 
Total current assets:458417225
Noncurrent Assets
Property, plant and equipment32174
Long-term investments and receivables2  
Long-term investments2  
Intangible assets, net (including goodwill)111214
Goodwill999
Intangible assets, net (excluding goodwill)236
Restricted cash and investments22 
Other noncurrent assets42
Prepaid expense and other noncurrent assets0
Other undisclosed noncurrent assets(4)(2) 
Total noncurrent assets:463118
TOTAL ASSETS:504448243
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities301710
Accounts payable323
Accrued liabilities22115
Employee-related liabilities632
Deferred revenue and credits 05
Other liabilities1  
Other undisclosed current liabilities(6)(3)(2)
Total current liabilities:251413
Noncurrent Liabilities
Liabilities, other than long-term debt64 
Other liabilities64 
Total noncurrent liabilities:64 
Total liabilities:311813
Stockholders' equity
Stockholders' equity attributable to parent473430230
Common stock000
Additional paid in capital920684389
Accumulated other comprehensive income (loss)(0)(0)0
Accumulated deficit(447)(254)(159)
Total stockholders' equity:473430230
TOTAL LIABILITIES AND EQUITY:504448243

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenue, net61315
Gross profit:61315
Operating expenses(199)(109)(58)
Other operating expense, net
(Other Expenses)
(1)  
Other undisclosed operating income1  
Operating loss:(192)(96)(43)
Nonoperating expense(4)(2)(0)
Investment income, nonoperating(4)(2)(0)
Loss from continuing operations before equity method investments, income taxes:(196)(98)(43)
Loss from equity method investments(1)  
Other undisclosed income from continuing operations before income taxes53 
Loss from continuing operations before income taxes:(192)(95)(43)
Income tax expense(1)(0) 
Net loss:(193)(95)(43)
Other undisclosed net income attributable to parent  0
Net loss available to common stockholders, diluted:(193)(95)(43)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net loss:(193)(95)(43)
Comprehensive loss:(193)(95)(43)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)0
Comprehensive loss, net of tax, attributable to parent:(193)(96)(43)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: